Gen-Probe's Analytical Service Laboratories Pass FDA Inspection
Gen-Probe’s Tepnel Pharma Service is pleased to announce that its analytical laboratories in Livingston, Scotland, have successfully passed a GMP inspection by the US Food and Drug Administration (FDA) without any “Form 483” citations. This is the second audit by the FDA since Tepnel relocated to its current facilities in 2008, and sits alongside the certification by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for GMP, GLP and GCP compliance at the site.
Carl Hull, CEO of Gen-Probe Incorporated, said, “This accomplishment reflects our long-standing corporate commitment to quality and regulatory compliance.”
Gen-Probe’s Tepnel Pharma Services is a global provider of outsourced services to the drug development industry. Tepnel specializes in providing pharmaceutical testing and research in the areas of batch release and stability testing, clinical trials support including bioanalysis and pharmacogenomics, and immunology.
Tepnel Pharma Services is an established brand of Gen-Probe Incorporated.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
